This is one of Vox's Future Perfect predictions for 2023; they give it a 50% probability.

In November, the nascent lab-grown or “cultivated” meat field reached a major milestone: The US Food and Drug Administration gave Upside Foods, an early player in the sector, the green light to sell its cultivated chicken. But you won’t find it for sale just yet — the startup still needs USDA approval, which I predict it’ll get by the end of 2023. Not only that: I predict similar approval for two other startups in the coming year.

If these moves happen, cell-cultured meat won’t be available for mass consumption immediately. Upside has plans to first partner with one Michelin-starred restaurant in San Francisco, and cultivated seafood startups Wildtype and BlueNalu will first work with high-end sushi restaurants. The first movers will have to be high-end — cultivated meat is still costly to produce, especially compared to $1.50-per-pound factory-farmed chicken.

Availability at just a few elite restaurants is far from the industry’s real ambition: stealing a sizable share of the conventional meat market. But it’s significant that the startups in a sector that began less than a decade ago are now slowly migrating from the R&D lab to the manufacturing plant. It’ll be the first real test for the $2 billion gamble on lab-made meat.

(Vox)

Resolves according to Vox Future Perfect's judgment at the end of the year.